Improved stroke prevention in atrial fibrillation after the introduction of non-Vitamin K antagonist oral anticoagulants: The Stockholm experience

Stroke

Volumn 49, Issue 9, 2018, Pages 2122-2128

  Forslund, Tomas ^a,b   Komen, Joris J ^c   Andersen, Morten ^d   Wettermark, Björn ^a,b   Von Euler, Mia ^a,e   Mantel Teeuwisse, Aukje K ^b   Braunschweig, Frieder ^f   Hjemdahl, Paul ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulants; Atrial fibrillation; Incidence; Stroke; Warfarin

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CLOPIDOGREL; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; ORAL ANTIDIABETIC AGENT; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; UNCLASSIFIED DRUG; WARFARIN; APIXABAN; DABIGATRAN; EDOXABAN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; RIVAROXABAN; THIAZOLE DERIVATIVE;

ADMINISTRATIVE CLAIMS (HEALTH CARE); ADOLESCENT; ADULT; AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHARMACY (DISCIPLINE); POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SECONDARY HEALTH CARE; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; COMPLICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; COHORT STUDIES; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PYRAZOLES; PYRIDINES; PYRIDONES; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; THIAZOLES; WARFARIN;

EID: 85055600660     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.118.021990     Document Type: Article

References (30)

1. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461-468. doi: 10.1111/joim.12114
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Circulation 1991;84:527-539. doi: 10.1161/01.CIR.84.2.527
4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
5. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817. doi: 10.1056/NEJMoa1007432
6. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary. Circulation 2006;114:700-752.
7. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol. 2013;170:208-214. doi: 10.1016/j.ijcard.2013.10.063
8. Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014;70:1477-1485. doi: 10.1007/s00228-014-1739-1
9. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44:3103-3108. doi: 10.1161/STROKEAHA.113.002329
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561
11. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doi: 10.1056/ NEJMoa1009638
12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039
13. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907
14. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2018;20:420-428. doi: 10.1093/europace/euw416
15. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta-analysis. Stroke. 2017;48:2494-2503. doi: 10.1161/STROKEAHA.117.017549
16. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-2962. doi: 10.1093/eurheartj/ehw210
17. Socialstyrelsen. Swedish National Guidelines for Cardiac Care 2015. https://www.socialstyrelsen.se/nationalguidelines/nationalguidelines forcardiaccare. Accessed June 15, 2018.
18. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104. doi: 10.1161/CIR.0000000000000040
19. Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al; GLORIA-AF Investigators. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF registry, phase II. Am J Med. 2015;128:1306-13.e1. doi: 10.1016/j.amjmed.2015.07.013
20. Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol. 2017;83:642-652. doi: 10.1111/bcp.13150
21. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF general pilot registry. Europace. 2015;17:1777-1786. doi: 10.1093/europace/euv269
22. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al; BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503. doi: 10.1016/S0140-6736(07)61233-1
23. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659-667. doi: 10.1007/s10654-009-9350-y
24. Wettermark B, Hammar N, Fored CM, MichaelFored C, Leimanis A, Otterblad Olausson P, et al. The new Swedish Prescribed Drug Register- opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16:726-735. doi: 10.1002/pds.1294
25. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272. doi: 10.1378/chest.09-1584
26. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100. doi: 10.1378/chest.10-0134
27. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass screening for untreated atrial fibrillation: The STROKESTOP study. Circulation. 2015;131:2176-2184. doi: 10.1161/ CIRCULATIONAHA.114.014343
28. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, et al. Device-detected atrial fibrillation and risk for stroke: an analysis of >10, 000 patients from the SOS AF project (Stroke prevention strategies based on atrial fibrillation information from implanted devices). Eur Heart J. 2014;35:508-516. doi: 10.1093/eurheartj/eht491
29. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al; Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet. 2004;363:1925-1933. doi: 10.1016/S0140-6736(04)16405-2
30. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, et al; Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health. 2013;1:e259-e281. doi: 10.1016/S2214-109X(13)70089-5